Myriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah
October 18 2016 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, announced today that more
than 40 of its employees are volunteering to support Project
BioEYES, which is a science, technology, engineering and math
(STEM) education program designed to teach K-12 students about cell
biology, genetics and careers in science. Employees will spend a
day in the classroom helping students formulate scientific
hypotheses, design experiments and collect data, as well as sharing
their own experiences from working in the life sciences.
“The BioEYES program is an ideal opportunity for us to support
STEM education in Utah. These programs benefit us all by inspiring
students to become tomorrow's innovators and pursue careers in the
sciences,” said Mark C. Capone, president and CEO. “Myriad has long
been one of the top STEM employers in the state, and we believe
that volunteering for programs like this benefits our employees,
our communities and our Company.”
Employees attended an orientation session to prepare for their
work in the classroom. They learned how to help the students
conduct experiments and understand what is entailed in research and
the scientific method.
“We are delighted to have the support of Myriad and its
employees in educating students about science,” said Judith
Neugebauer, Ph.D., BioEYES Utah Program Manager. “These volunteers
will help us offer the students opportunities to explore the life
sciences by conducting real experiments and sharing their passion
for science. Together, we will introduce children to the thrill of
scientific discovery.”
For more information, follow us on Twitter via @bioeyes and
@MyriadGenetics.
About BioEYESBioEYES is a K-12 science
education program, sponsored by the Department of Pediatrics at the
University of Utah that provides active, inquiry-based learning
opportunities through the use of live zebrafish. During their
program week, students explore both adult and embryonic zebrafish
and, by week’s end, they examine the beating heart and blood cells
of the zebrafish larvae. The program is designed to incorporate
teacher empowerment and provides professional development seminars
and a co-teaching experience with trained science consultants,
called outreach educators. BioEYES is located at the University of
Pennsylvania in Philadelphia, PA; the Carnegie Institution for
Science in Baltimore, MD; Monash University in Melbourne,
Australia; and the University of Utah in Salt Lake City, UT. Since
its inception it has reached over 100,000 students.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on three
strategic imperatives: transitioning and expanding its hereditary
cancer testing markets, diversifying its product portfolio through
the introduction of new products and increasing the revenue
contribution from international markets. For more information on
how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra,
Prolaris and GeneSight are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024